![]() |
市场调查报告书
商品编码
1384857
介入性心臟器材全球市场规模、份额、产业趋势分析报告:2023-2030 年按应用、产品和地区分類的展望和预测Global Interventional Cardiology Devices Market Size, Share & Industry Trends Analysis Report By End-use (Hospitals & Clinics, Ambulatory Surgical Centers & Others), By Product, By Regional Outlook and Forecast, 2023 - 2030 |
到 2030 年,介入性心臟器材市场规模预计将达到 219 亿美元,预测期内CAGR为 7.4%。 2022年市场规模为62,105,000台,成长率为7.3%(2019-2022年)。
根据 KBV Cardinal 矩阵中的分析,雅培实验室和美敦力公司是介入心臟设备市场的先驱。 Terumo Corporation、Boston Scientific Corporation 和 Teleflex, Inc. 等公司是介入心臟设备市场的主要创新者。 2021 年 9 月,Terumo 与 Etiometry 合作,让临床医师更深入了解病患的病情。
COVID-19 影响分析
在大流行的早期阶段,许多择期和非紧急介入心臟手术被推迟或取消,以优先治疗 COVID-19 患者并节省医疗资源。这导致心血管手术和相关设备的使用暂时下降。医院和医疗机构已将重点转移到治疗急性心肌梗塞(心臟病发作)等紧急、高优先病例。支架、导管和导管导引线等介入性心臟器械的生产和分销延迟影响了市场。由于需要限制面对面的互动并降低病毒传播的风险,人们开始关注心臟病患者的远端监测。因此,COVID-19的爆发对市场产生了温和的影响。
市场成长要素
心血管疾病盛行率增加
心血管疾病(CVD),如冠状动脉疾病(CAD)、心臟病和心臟衰竭,仍然是全世界发病和死亡的主要原因。 CVD 的日益普及正在推动对介入性心臟病学手术和设备的需求。心血管疾病是全世界发病和死亡的主要原因之一。数百万人受到影响,需要诊断和治疗的患者数量庞大。随着世界人口高龄化,与老龄化相关的心血管疾病的发生率也增加。老年人更容易患心血管疾病,增加了对心血管干预措施和设备的需求。全球心血管疾病负担持续增加,介入心臟设备市场预计将扩大,以满足不断增长的医疗保健需求。
人口高龄化比例增加
随着世界人口高龄化,与老龄化相关的心血管疾病的发生率不断增加。老年人更有可能需要介入性心臟病学干预,例如置入术和血管成形术。老龄化是冠状动脉疾病 (CAD)、心臟病、心臟衰竭和心律不整等心血管疾病 (CVD) 的主要危险因子。随着老龄化,我们更有可能患上这些疾病,从而增加了对介入性心臟病学手术和设备的需求。老龄化与冠状动脉中动脉粥状硬化斑块的进行性累积有关。因此,老年人发生急性冠状动脉事件(例如心臟病)的风险增加,需要紧急介入。这些技术将推动市场成长,同时增加介入性心臟设备的可用性并改善患者的治疗结果和医疗保健效率。
市场抑制因素
高成本、经济压力大
然而,介入心臟设备的高成本可能会导致医疗保健预算紧张,并限制获得先进治疗的机会,特别是在资源有限的环境中。平衡创新和承受能力是一个持续的挑战。药物释放型支架、球囊和诊断成像设备等介入心臟设备的製造和购买成本昂贵。高昂的初期成本可能会导致医疗保健预算紧张,并限制获得先进治疗和技术的机会,特别是在资源有限的地区。监管变化、更新以及指南不断变化的解释可能会在核准过程中产生不确定性。监管决策的延迟可能会影响市场进入时间表。
按最终用途分類的展望
依最终用途划分,市场分为医院和诊所、门诊手术中心等。 2022 年,门诊手术中心在市场上占据了很大的收益占有率。门诊手术中心(ASC)适合进行心导管插入术、血管成形术及支架置入术等微创介入性心臟病手术。患者受益于微创方法,包括更快的恢復时间和更少的术后不适。 ASC 的密集、以患者为中心的环境带来了更积极和个体化的患者体验。由于进入门槛比医院低,病患的焦虑和压力也减轻了。
产品展望
依产品分类,产品分为冠状动脉支架、 PTCA球囊导管、附属器械等。在2022年的市场中, PTCA球囊导管细分市场将占据重要的收益占有率。随着全球冠状动脉疾病 (CAD) 盛行率的上升,对PTCA球囊导管的需求预计将会成长。由于 CAD 仍然是发病和死亡的主要原因,对血管成形术等介入手术的持续需求正在推动PTCA球囊导管的使用。 PTCA球囊导管是微创血管成形术的重要组成部分,作为传统心臟直视手术的替代方案越来越受欢迎。由于恢復时间更快和住院时间更短,患者通常更喜欢侵入性较小的方法。 PTCA球囊导管已发展到可以解决更复杂和更困难的病变,例如严重钙化的动脉。针对这种情况设计的专用球囊导管正在扩大可治疗的患者范围。
冠状动脉支架的前景
冠状动脉支架市场分为药物释放型支架、裸金属支架和生物可吸收支架。裸金属支架 (BMS) 领域在 2022 年获得了巨大的市场收益占有率。 BMS是一种由不銹钢或钴铬合金製成的金属支架。不使用药物涂层。由于缺乏药物涂层,BMS 通常需要较短持续时间的双重抗血小板治疗 (DAPT)。当延长 DAPT 增加出血风险时,这是有利的。
PTCA球囊导管的前景
PTCA球囊导管市场分为常规型、特殊型和药物涂层型。 2022 年,常规细分市场获得了最大的销售份额并主导了市场。介入性心臟病学通常可以改善患者预后、减轻症状并提高生活品质。它可以恢復心臟的正常血流,缓解胸痛和气短等症状。许多介入器械,例如药物释放型支架,可以帮助降低血管再阻塞或动脉血管再阻塞的风险,并减少重复介入的需要。微创手术通常可以减轻疼痛、缩短住院时间、更快恢復正常活动并提高患者舒适度。
附属设备的展望
在辅助设备方面,市场分为 PTCA导管导引线、诊断导管、PTCA引导管和导引鞘。 2022年,PTCA导管导引线部门市场的销售比重最大。主力导管导引线用于引导冠状动脉并穿过病变(闭塞或狭窄)以到达血管内的目标部位。为使用其他介入设备(例如球囊导管和支架)提供初始通道和支援。这些导管导引线有助于将导管引导至冠状动脉内的所需位置。
区域展望
从区域来看,我们对北美、欧洲、亚太地区和拉丁美洲地区的市场进行了分析。 2022年,亚太地区在市场中获得了显着的收益占有率。亚太地区心血管疾病 (CVD) 的负担不断增加,包括冠状动脉疾病 (CAD)、中风和高血压。生活方式的改变、都市化和高龄化等因素导致心血管疾病盛行率上升。许多亚太国家的经济成长导致医疗保健支出增加,从而扩大了医疗保健设施,引进了先进的医疗技术,并改善了介入性心臟病学治疗的机会。
The Global Interventional Cardiology Devices Market size is expected to reach $21.9 billion by 2030, rising at a market growth of 7.4% CAGR during the forecast period. In the year 2022, the market attained a volume of 62,100.5 thousand units experiencing a growth of 7.3% (2019-2022).
The drug coating on drug eluting stents (DES) elutes slowly over time, inhibiting tissue growth that can lead to restenosis. This has led to improved long-term outcomes for patients. Consequently, the drug eluting stents segment would generate approximately 53.1% share of the market by 2030. The lower restenosis rates associated with DES have reduced the need for repeat interventions, such as additional angioplasty or stent placement. This translates to improved patient outcomes and reduced healthcare costs. DES has been associated with a lower risk of stent thrombosis (a potentially life-threatening complication), particularly when patients adhere to dual antiplatelet therapy (DAPT).
The major strategies followed by the market participants are Partnerships, Collaborations & Agreements as the key developmental strategy to keep pace with the changing demands of end users. For instance, In June, 2023, Koninklijke Philips N.V. collaborated with Biotronik, to widen the range of cardiovascular devices available for Philips SymphonySuite customers. In January, 2023, Terumo collaborated with Siemens Healthineers, to make better heart care available to more people.
Based on the Analysis presented in the KBV Cardinal matrix; Abbott Laboratories and Medtronic PLC are the forerunners in the Interventional Cardiology Devices Market. Companies such as Terumo Corporation, Boston Scientific Corporation and Teleflex, Inc. are some of the key innovators in the Interventional Cardiology Devices Market. In September 2021, Terumo came into collaboration with Etiometry, to provide clinicians with an in-depth understanding of the patient's condition.
COVID-19 Impact Analysis
During the early stages of the pandemic, many elective and non-urgent interventional cardiology procedures were postponed or canceled to prioritize the treatment of COVID-19 patients and to conserve healthcare resources. This led to a temporary decline in cardiac procedures and reduced use of related devices. Hospitals and healthcare facilities shifted their focus toward treating emergent and high-priority cases, such as acute myocardial infarctions (heart attacks), which continued to require interventional cardiology procedures. Delays in producing and distributing interventional cardiology devices, including stents, catheters, and guidewires, affected the market. With the need to limit in-person interactions and reduce the risk of virus transmission, there was a greater emphasis on remote monitoring of cardiac patients. Thus, the COVID-19 pandemic had a moderate effect on the market.
Market Growth Factors
Increasing prevalence of cardiovascular diseases
Cardiovascular diseases (CVDs) such as coronary artery disease (CAD), heart attacks, and heart failure remain a leading cause of morbidity and mortality globally. The growing prevalence of CVDs drives the demand for interventional cardiology procedures and devices. Cardiovascular diseases are among the leading causes of morbidity and mortality globally. They affect millions of people, resulting in a substantial patient population in need of diagnosis and treatment. As the global population ages, there is a higher incidence of age-related cardiovascular conditions. Older adults are more susceptible to CVDs, increasing the demand for cardiovascular interventions and devices. As the global burden of CVDs continues to increase, the market for interventional cardiology devices is expected to expand to meet the growing healthcare needs.
Rising proportion of the aging population
As the global population ages, there is a higher incidence of age-related cardiovascular conditions. Older adults are more likely to require interventional cardiology interventions, such as stenting and angioplasty. Aging is a major risk factor for cardiovascular diseases (CVDs) such as coronary artery disease (CAD), heart attacks, heart failure, and arrhythmias. Individuals are more likely to develop these conditions as they age, leading to an increased demand for interventional cardiology procedures and devices. Aging is associated with the progressive buildup of atherosclerotic plaques in the coronary arteries. As a result, older individuals are at a higher risk of experiencing acute coronary events, such as heart attacks, which require urgent intervention. These technologies enhance the utilization of interventional cardiology devices, driving market growth while improving patient outcomes and healthcare efficiency.
Market Restraining Factors
High cost and economic pressures
However, the high cost of interventional cardiology devices can strain healthcare budgets and limit access to advanced treatments, especially in resource-constrained settings. Striking a balance between innovation and affordability is a persistent challenge. Interventional cardiology devices, such as drug-eluting stents, balloons, and imaging equipment, can be expensive to manufacture and purchase. The high upfront costs can strain healthcare budgets, limiting access to advanced treatments and technologies, particularly in regions with limited resources. Regulatory changes, updates, or evolving interpretations of guidelines can introduce uncertainty into the approval process. Delays in regulatory decisions can impact market entry timelines.
End-use Outlook
By end-use, the market is segmented into hospitals & clinics, ambulatory surgical centers, and others. The ambulatory surgical centers garnered a significant revenue share in market in 2022. Ambulatory surgical centers (ASCs) are well-suited for minimally invasive interventional cardiology procedures, such as cardiac catheterization, angioplasty, and stent placement. Patients benefit from less invasive approaches, leading to quicker recovery times and reduced post-operative discomfort. The focused and patient-centered environment of ASCs can result in a more positive and personalized patient experience. The setting is often less intimidating than a hospital, which can reduce anxiety and stress for patients.
Product Outlook
By product, the market is categorized into coronary stents, PTCA balloon catheters, accessory devices, and others. The PTCA balloon catheters segment covered a considerable revenue share in the market in 2022. The demand for PTCA balloon catheters is expected to grow in line with the increasing prevalence of coronary artery disease (CAD) globally. As CAD remains a leading cause of morbidity and mortality, there is a continued need for interventional procedures, including angioplasty, which drives the use of PTCA balloon catheters. PTCA balloon catheters are integral to minimally invasive angioplasty procedures, which have gained popularity over traditional open-heart surgeries. Patients often prefer these less invasive approaches because they offer shorter recovery times and reduced hospital stays. PTCA balloon catheters have evolved to address more complex and challenging lesions like heavily calcified arteries. Specialized balloon catheters designed for these situations have expanded the range of treatable patients.
Coronary Stents Outlook
Under coronary stents, the market is segmented into drug eluting stents, bare metal stents, and bioabsorbable stents. The bare metal stents (BMS) segment acquired a substantial revenue share in the market in 2022. BMS are metallic stents made from stainless steel or cobalt-chromium alloys. They do not have drug coating. Due to the absence of a drug coating, BMS typically requires a shorter duration of dual antiplatelet therapy (DAPT). This can be advantageous when extended DAPT poses a higher bleeding risk.
PTCA Balloon Catheters Outlook
Under PTCA balloon catheters, the market is fragmented into normal, specialty, and drug coated. In 2022, the normal segment dominated the market with the maximum revenue share. Interventional cardiology procedures often improve patient outcomes, reduce symptoms, and enhance quality of life. They can help restore normal blood flow to the heart and alleviate chest pain, shortness of breath, and other symptoms. Many interventional devices, such as drug-eluting stents, help reduce the risk of restenosis and re-narrowing of arteries, reducing the need for repeat interventions. Minimally invasive procedures are generally associated with less pain, shorter hospital stays, and a quicker return to normal activities, leading to greater patient comfort.
Accessory Devices Outlook
Under accessory devices, the market is classified into PTCA guidewires, diagnostic catheters, PTCA guiding catheters, and introducer sheaths. In 2022, the PTCA guidewires segment registered the maximum revenue share in the market. Workhorse guidewires are used to navigate through coronary arteries and cross lesions (blockages or stenoses) to reach the target site within the vessel. They provide the initial access and support for delivering other interventional devices, such as balloon catheters and stents. These guidewires help guide catheters to the desired location within the coronary arteries.
Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region acquired a significant revenue share in the market. Asia Pacific is witnessing a growing burden of cardiovascular diseases (CVDs), including coronary artery disease (CAD), stroke, and hypertension. Factors like lifestyle changes, urbanization, and an aging population contribute to the increased prevalence of CVDs. Economic growth in many Asia Pacific countries has led to increased healthcare spending, enabling the expansion of healthcare facilities, the adoption of advanced medical technologies, and improved access to interventional cardiology procedures.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Abbott Laboratories, Boston Scientific Corporation, Terumo Corporation, Medtronic PLC, B. Braun Melsungen AG , Biotronik SE & Co. KG , Cardinal Health, Inc. , Teleflex, Inc. , Koninklijke Philips N.V. ,Alvimedica
Recent Strategies Deployed in Interventional Cardiology Devices Market
Mergers & Acquisition
Feb-2023: Abbott Laboratories took over Cardiovascular Systems, Inc., a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease. The acquisition of CSI enhances Abbott's vascular device offerings portfolio.
Aug-2022: Medtronic completed the acquisition of Affera, a US-based developer of medical devices. The acquisition of Affera broadens the acquiring company's cardiac ablation platform.
Feb-2022: Boston Scientific completed the acquisition of Baylis Medical Company, a Canada-based developer of medical devices. This acquisition enables the acquiring company to incorporate Baylis' platforms within its existing electrophysiology and structural heart offerings, thereby reinforcing its market position.
Product Launches and Product Expansions
Aug-2022: Medtronic PLC launched the Onyx Frontier drug-eluting stent (DES), the Onyx Frontier DES is employed in the management of individuals suffering from coronary artery disease (CAD), a condition resulting from the accumulation of plaque within the coronary arteries. The Onyx Frontier drug-eluting stent (DES) features matrix sizes ranging from 2.0mm to 5.0mm diameters, with the expandability of sizes from 4.50-5.00mm.
Jul-2021: Medtronic PLC introduced the Prevail drug-coated balloon (DCB) Catheter. The Prevail DCB employs a fast-absorbing drug, paclitaxel, to facilitate the treatment of de novo lesions, small vessel disease, and in-stent restenosis (ISR). The Prevail DCB would be utilized in percutaneous coronary intervention (PCI) procedures to address narrowed or obstructed coronary arteries in patients diagnosed with coronary artery disease (CAD).
Partnerships, Collaborations & Agreements
Jun-2023: Koninklijke Philips N.V. collaborated with Biotronik, a multi-national cardiovascular biomedical research and technology company. This collaboration aimed to widen the range of cardiovascular devices available for Philips SymphonySuite customers.
Jan-2023: Terumo collaborated with Siemens Healthineers, a medical technology company. The collaboration focuses on reinforcing cardiac care in India. This collaboration aims at making better heart care available to more people.
Sep-2021: Terumo came into collaboration with Etiometry, a US-based provider of clinic decision-support software. The collaboration involves introducing clinical decision support to cardiac surgery patients. Integrating Etiometry's platform with the surgical devices company's devices would provide clinicians with an in-depth understanding of the patient's condition.
Mar-2021: Braun Interventional Systems joined hands with Infraredx, designs, develops, manufactures, and distributes medical devices. Together the companies aimed to boost the FDA investigational device exemption clinical test for the SeQuent Please ReX drug coated PTCA balloon catheter. Additionally, The SeQuent Please ReX drug-coated PTCA balloon catheter is developed to cure coronary in-stent restenosis, or the incremental re-narrowing of a coronary artery following stent transplantation.
Approvals
May-2022: Medtronic PLC received FDA approval for the Onyx Frontier drug-eluting stent (DES). Onyx Frontier DES is aimed at the care of individuals afflicted with coronary artery disease (CAD), a condition initiated by the accumulation of plaque within the coronary artery walls.
Feb-2022: Medtronic plc received a U.S. Food and Drug Administration approval for Freezer and Freezer Xtra Catheters for the treatment of paediatric Atrioventricular Nodal Re-entrant Tachycardia. Catheter ablation is resilient, one-use equipment used to freeze cardiac tissue and block unnecessary electrical signals within the heart. Additionally, Freezer and Freezer Xtra are the first-line antidote for the treatment of AVNRT.
Market Segments covered in the Report:
By End-Use (Volume, Thousand Units, USD Million, 2019-2030)
By Product (Volume, Thousand Units, USD Million, 2019-2030)
By Geography (Volume, Thousand Units, USD Million, 2019-2030)
Companies Profiled
Unique Offerings from KBV Research